Matthew Key argues patent value depends on molecular proximity and replication difficulty, not just legal protection.
Summary
Matthew Key discusses the varying value of patents for startups, contrasting weak 'grass hedge' protections with strong 'Great Wall' defenses. He outlines three key variables: proximity to the molecular level, the percentage of the product required for replication, and the business model. Key uses case studies of a beach bag company and a chemistry startup to illustrate how patents can be ineffective or critical depending on the industry. He also warns that patents can serve as liabilities by providing competitors with blueprints to design around, particularly in software where network effects matter more.
Key takeaways
Episode sections
- 0:00 – 1:39
Introduction and Personal Anecdote
Speaker Matthew Key introduces the topic of patents in startups, sharing his experience as a former founder of a bond trading startup where he pursued patent protection for an algorithm. He notes that while patents provided credibility, their actual business impact was unclear.
- 1:39 – 2:58
Investor Perspective on Patent Value
Key argues that patents are often a distraction for many startups, stating that IP does not generate revenue on its own. He asserts that patents can range from being as weak as a 'grass hedge' to as strong as the 'Great Wall of China,' depending on specific variables.
- 2:58 – 4:18
Three Variables Determining Patent Value
The speaker outlines three factors that determine patent value: proximity to the molecular level, the percentage of the product needed to be replicated to create a duplicate, and the business model (mass market vs. technical). He cites Eric Berry of Avery Averant and Capital regarding the importance of protecting replicable elements.
- 4:18 – 6:57
Case Study: Bog Bag
Key discusses the 'Bog Bag,' a beach bag company that held a patent but faced significant competition from cheaper duplicates. He notes that the patent was ineffective ('grass hedge') because the product was easy to manufacture and the market was price-sensitive, leading to a brand-focused defensibility strategy instead.
- 6:57 – 7:37
Case Study: Startup 2 (Chemistry/Pharma)
Contrasting the Bog Bag, Key describes a startup with molecular-level chemistry innovations applicable to big pharma. For this company, patents are critical ('Great Wall') because they protect hard-to-replicate science and allow the company to 'own the space' for licensing or acquisition.
- 7:37 – 9:17
Patents as Liability and Software Patents
Key warns that patents can become liabilities by providing blueprints for competitors to design around. He states that investors place little to no value on software patents, arguing that software defensibility relies on network effects, data moats, and speed rather than IP.
- 9:17 – 10:27
Outcome of Personal Patent Application
Key reveals that his own bond trading algorithm patent application was rejected by the examiner as non-patentable subject matter. He concludes that patent importance varies by product type and advises founders to seek advice beyond patent attorneys.
Claims worth verifying
The speaker engaged an IP attorney in August 2014 and filed a utility patent application six months later for a bond trading algorithm.
Unidentified speaker (speaker_0) ·0:59
How to verify: Check USPTO patent application records for the speaker's former company (Matthew Key's bond trading startup) filed around February 2026. For recent events, verify 2026-08-21 through 2026-11-21. Use another period only when the speaker explicitly names it.
Eric Berry is from Avery Averant and Capital, a New York-based VC firm investing in the intersection of technology and healthcare.
Unidentified speaker (speaker_0) ·3:58
How to verify: Search SEC Form ADV filings for 'Avery Averant and Capital' or 'Avron Capital' (note: transcript says both, verify correct name) on EDGAR or the firm's website. For recent events, verify 2026-08-21 through 2026-11-21. Use another period only when the speaker explicitly names it.
Primary sourceBog Bag alternatives were priced at an average of 40% less than the original Bog Bag.
Unidentified speaker (speaker_0) ·4:58
How to verify: Search historical Google Shopping or retail archives for 'Bog Bag' and its competitors to compare prices circa 2026. For recent events, verify 2026-08-21 through 2026-11-21. Use another period only when the speaker explicitly names it.
The Bog Bag founder included a note saying 'thank you for buying the original' inside the product.
Unidentified speaker (speaker_0) ·5:57
How to verify: Search for press releases, interviews, or social media posts by the Bog Bag founder discussing this specific packaging detail. For recent events, verify 2026-08-21 through 2026-11-21. Use another period only when the speaker explicitly names it.
The speaker's patent application was rejected as 'non patentable subject matter' in an office action.
Unidentified speaker (speaker_0) ·9:17
How to verify: Check USPTO PAIR or patent application records for the speaker's former company for an office action rejection under 35 U.S.C. 101. For recent events, verify 2026-08-21 through 2026-11-21. Use another period only when the speaker explicitly names it.
Avery Averant and Capital (or Avron Capital) is interested in proprietary data, distribution, and workflow integration for AI and software-driven healthcare companies.
Unidentified speaker (speaker_0) ·8:57
How to verify: Review investment thesis documents or press releases from the firm regarding their criteria for software/AI healthcare investments. For recent events, verify 2026-08-21 through 2026-11-21. Use another period only when the speaker explicitly names it.
Do your own research
- Review the specific patent applications filed by the Bog Bag company to assess their scope and enforcement history.
- Analyze the chemical composition patents of the chemistry startup to verify their molecular-level uniqueness.
- Check USPTO records for the rejection of Matthew Key's bond trading algorithm patent to understand software patentability standards.
- Compare the pricing strategies of the Bog Bag against its competitors to quantify the impact of patent ineffectiveness on market share.
- Investigate the network effects and data moats of leading software startups to validate the claim that patents are irrelevant in this sector.
- Consult with patent attorneys specializing in software vs. chemistry to understand the differing defensibility strategies.
- Review investor term sheets for the featured startups to see if patent portfolios were included in valuation metrics.
Full transcriptexpand
0:00Unidentified speaker (speaker_0): Hey, this is Matthew Key, and this is the Tundra Angels Angle. If you're new to this newsletter, I write weekly insetter tactics as an investor that I wish I would have known 10 years ago as a startup founder. This week's article is called A Grass Hedge or a Great Wall The Misunderstood Dynamics of Patents. Let's dive in. One area of startups that seems to be misunderstood is the level of importance of patents. When I was a founder, this is an area that I fell into hook, line, and sinker. Until I became an investor, I lacked context on how much intellectual property mattered, when it mattered and when it may just be a distraction. I wish I would have known this 10 years ago. So I wanted to write to my former founder self here. Previously I co-founded a bond trading startup. Specifically my father was my co-founder and he was a technical person that sold bond trading software to the largest banks and asset managers. He had developed an algorithm that conceptualized bonds so that a professional bond trader could use the algorithm to help move a client's portfolio toward their intended targets. I do think that the way the algorithm conceptualized bonds was novel. And my father was very adamant about getting a patent protection for the algorithm. We engaged with an IP attorney in August 2014 and then six months later filed the utility patent application. And from then on, we were able to say a very key phrase we have a patent pending algorithm. We felt
1:19sophisticated, we felt credible. But besides giving us good vibes, how much did a patent actually matter to our business? A disclaimer, this may be discouraging. Fast forward to this side of the table, the investor side of the table. I encounter a ton of founders that have applied for or are considering or developing currently patent protection. For some founders, this article may be very discouraging. I don't want to hurt your feelings, but I do want you to know the truth. And sometimes the truth hurts. The default assumption tends to be that patents matter significantly, no matter what. What I would tell my former founder self is this: In some startups, patents matter a lot. These startups should absolutely be applying for patents. But in other startups, patents hold very little significance. In those cases, patents are often just a complete distraction. Regardless, in any company, IP is just one part of your business, and IP doesn't generate revenue by itself. It doesn't have magnetic properties such that all the customers in your market will be throwing money at you hand over fist to license what you have. There is no patent it and they will come. Yet I encounter a surprising number of founders whose actions convey they believe this. There is a magnificent amount of work needed to be done to stimulate the market demand for your product. Startups that asymmetrically win in the market are the ones that create an unfair advantage to capture
2:38the demand in the market. Patents by itself do not move the market into buying cycles. How investors view patents. Patents can either be as feeble as a grass hedge or as durable as a great wall of China. I want to help give founders some direction in terms of when it might make sense. The importance of patents varies on what is being patented. In my view, the product's proximity to the molecular level in proportion to the risk of duplicates, in proportion to the business model. So three quick variables. In my view, the closer the patent is to the molecular level, the more valuable patent protection tends to be for the company. Or put the opposite way. the farther a patent is from the molecular level, the less valuable patent protection tends to be for the company. Number two, second variable: the percentage of the product that needs to be replicated to functionally serve as a duplicate to the market. Can a competitor copy 50 to 90% of a product and still have it be functionally relevant to the market? I'll gonna give an example in the anecdote below. Or does a competitor absolutely need to copy 100% of it to have the product function? And see the example of startup two later on in this article. And then the third variable is the business model, the mass market consumer versus highly technical market to relative to how it's sold. Now, additionally, for this article, I pinged a number of investors from different industries about
3:58how they view the importance of patents. And Eric Berry of Avery Averant and Capital, Capital, New York. a New York-based VC firm that invests in the intersection of technology and healthcare, mentioned, quote, where Averant invests, the importance of patents varies enormously by business model. A patent portfolio is only valuable to the extent that it protects something competitors can actually need to replicate. The bog bag bounce. Over the summer, my family was in need of a new beach bag. My wife saw an ad for the bog bag. It was and very interesting. interested in it. Through searching, I typed bog bag into Google and discovered that the top three search terms after typing that are listed in the screenshot bog bag dupe and bog bag versus bog bag alternatives. Being a former founder and startup investor, I immediately became troubled for the company. People are actively searching for bog bag duplicates. The function and utility of the bog bag versus the duplicates. were virtually the same. And also the other alternatives were priced at an average of 40% less than the original bog bag. And so the decision ultimately became about making a brand decision relative to the price. How much do we want to have the bog bag brand? Is it worth the price? But then I discovered something interesting. Through additional research, I discovered the patent company had a patent and it's hyperlinked in the article. In the case of Bog Bag, the patent by itself was
5:18as feeble as a grass hedge for defensibility. Duplicate products are still prevalent. It wasn't about the patent. Because the product was easy to make, the risk of duplicates that could design around the infringement and drastically undercut the pricing of the original was very high. Additionally, the business model is of a lower-priced lower priced product to mass market consumers. This category is ripe for patent infringement. Buying the original but falling for the duplicate. My wife decided to buy the bog bag. When my wife opened up the bog bag, she found a note from the founder. And one of the things the founder wrote in the note was, thank you for buying the original. End quote. I found this phrase both illuminating and unfortunate. The founder had surrendered to the brutal truth that her product was a magnet of opportunity. for duplicates. This founder knew that the only defensibility tactic the company possessed was a brand play. Thank you for buying the original. But the fact that the price was 40% less continued to make my wife and I second guess the decision. Do we really need the bog bag? Can we save those 50 bucks? In the end, after And a week or two, we ended up returning the bog bag, instead, opting for a version at a larger retailer that everyone would. know. The fact that we have four young boys would probably rip it apart anyway, uh, did play into that decision too. And in the end, I know, uh I'm an investor, but I'm also a consumer. The takeaway is that this
6:37company had a patent, and it hardly mattered. Duplicates were steadily taking away their market share. Patents could either be as effective as a grass hedge or as robust as a the Great Wall of China. If an incumbent acquires a company, will the value of the intellectual product pretty be such an outsized asset that they're willing to pay a premium for the company? Startup 2. Startup 2. Contrast this with another startup, call it Startup 2, that has a chemistry innovation with applicability to big pharma companies. The founding team has several layers of patents. Some approved patents, some pending patents. This is a much different situation than the first startup above. Instead of being easily manufactured, this startup's product. quote unquote, exists at the molecular level. In the case of this startup, the founding team described their intention is to quote, own the space of this chemistry for the big pharma industry. The team further said, the intention with the patent protection is to quote own the key that unlocks many doors, end quote. This second company is trying to own the space of this chemistry. How do I do that? How do they do that? That's where patents become extremely important and part. and parcel of the value of the company. When patents become a liability. For some products, especially when the patent is far from the molecular level, the patent could actually become a liability. I recently spoke with a physical product design firm and the founder told me that on a numerous of occasions, clients have hired them to design a workaround to a product that has
7:57patent protection. In cases like this, the patent basically provides a blueprint and the boundary lines. of how one might design around it so as to not infringe on the patent. This is a real dynamic and it must be highly considered. Patents on software. Here is one major area of founder misconception. Investors place little to no value on software patents. For myself, I have never seen one positive example where a software patent added monetizable value to a startup. Never say never, but that's all. over six years of startup deal flow. If a physical product may not be better than a grass hedge of defensibility, then a software product may be no more than a few fig leaves. My big question related to software related patents are why would you make it explicitly clear to any other competitive software companies the boundary lines they need to design around to recreate it? The defensibility of software doesn't lie in a few fig leaves leagues of a patent, but rather in network effects, the data mode, the speed of scale in the brand. And Eric of Avron Capital said the same thing, saying, quote, for novel medical devices, diagnostics, and other hard technologies, patents can be critical to protecting years of RD. But for AI and software-driven healthcare companies, we're generally much more interested in proprietary data, distribution, workflow integration, and the ability to execute quickly. End quote. Oh, and by the way. two and a half years after my company
9:17first applied for the software patent, the IP attorney sent us this email. It's basically a screenshot of an email where it says that in the office action, the examiner rejects the claims as being unclear, directed to non patentable subject matter, and unpatentable over a combination of the attached references. Our options were spend the additional time and money to try to rebuff the patent examiner's review, or let it ride. And all the hundreds of hours and tens of thousands of dollars would go with it. The value of importance of patents depends on what is being patented, the product's proximity to the molecular level, in proportion to the risk of duplicates, in proportion to the business model. Depending on the company, a patent isn't just a distraction, but a money hole. Put another way, when considering patent protection, seek advice from someone else besides your patent attorney, VCs, other founders in the space, etc. Because there's nothing worse than spending hundreds of hours and tens of thousands of dollars just to fortify a grass hedge. Thanks for checking out the Tundra Angels angle. Hit the link below to access all the articles I've written. I'm just gonna highlight a couple here. The same revenue, but three years later. Why we pass on the startup, when the silence speaks, and in an open relationship with the truth. As always, let me know your thoughts, comments, questions. Thanks everybody.